Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration

By L. Walter, A. Franklin, Anke Witting, C. Wade, Yiheng Xie, George Kunos, K. Mackie, N. Stella. Journal of Neuroscience, 2003

670 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Cognitive Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/3b6d6a9ec73eee3795a8bf4821b0e7ce565709d7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. R. Pertwee
2. George Kunos
3. K. Mackie
4. P. Pacher
5. S. Batkai
6. Hui-Chen Lu
7. M. Guzmán
8. T. Klein

In Cognitive Neuroscience

1. R. Pertwee
2. Hui-Chen Lu
3. K. Mackie
4. George Kunos

In Pharmacology

1. R. Pertwee
2. George Kunos
3. P. Pacher
4. S. Batkai
5. K. Mackie
6. T. Klein
7. P. Greasley
8. Hui-Chen Lu

Citations in the corpus

• Cannabinoid-based drugs as anti-inflammatory therapeutics (2005, background): “Consistent with a possible role for endocannabinoids and CB 2 in chemotaxis and other immune-activation events, a recent study of mouse brain microglial cells showed that, under chemotactic conditions, the expression of CB 2 was specifically localized to the leading edge of the cel”
• The orphan receptor GPR55 is a novel cannabinoid receptor (2007, background): “…mainly in immune cells with particularly high levels in B cells and natural killer cells (Galiegue et al., 1995) although it has been reported that the CB2 receptor is expressed in microglia cells of the CNS (Walter et al., 2003) and in brain stem neuronal cells (Van Sickle et al., 2005).”
• CB2: a cannabinoid receptor with an identity crisis (2010, background): “CB2 modulates microglial migration and infiltration into brain areas with active neuroinflammation and degeneration (Walter et al., 2003; Ashton et al., 2007; Fernandez-Ruiz et al., 2008; Miller and Stella, 2008; Price et al., 2009).”
• An introduction to the endogenous cannabinoid system (2015, background): “This receptor is primarily present in microglia and vascular elements (25, 26).”
• Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation (2005, background): “As expected, microglia in culture expressed both CB 1 and CB 2 receptors (Walter et al., 2003) (Fig.”
• Pharmacological actions of cannabinoids. (2005, background): “it has been proposed that microglial CB2 receptors and abnormal-cannabidiol receptors interact in a synergistic manner when triggering the migration of microglial cells (Walter et al. 2003).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “Atypical cannabinoid receptors with pharmacological properties similar to those of the endothelial receptor have been postulated to exist on microglia, where they mediate microglial migration (Walter et al., 2003), and on neurons of the mouse vas deferens (Pertwee et al., 2002, 2005c).”
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin (2008, background): “…cell migration and reduce clinical signs of inflammation (Lunn et al., 2006) and that CBD is a potent inhibitor of evoked migration in the Boyden chamber both of murine microglial cells and macrophages (Walter et al., 2003; Sacerdote et al., 2005) and of human neutrophils (McHugh and Ross, 2005).”